578 related articles for article (PubMed ID: 20959606)
81. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
So L; Fruman DA
Biochem J; 2012 Mar; 442(3):465-81. PubMed ID: 22364281
[TBL] [Abstract][Full Text] [Related]
82. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K; Graupera M; Vanhaesebroeck B
Cancer Discov; 2016 Oct; 6(10):1090-1105. PubMed ID: 27655435
[TBL] [Abstract][Full Text] [Related]
83. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
Pauls SD; Lafarge ST; Landego I; Zhang T; Marshall AJ
Front Immunol; 2012; 3():224. PubMed ID: 22908014
[TBL] [Abstract][Full Text] [Related]
84. Two birds with one stone: dual p110δ and p110γ inhibition.
Okkenhaug K
Chem Biol; 2013 Nov; 20(11):1309-10. PubMed ID: 24267274
[TBL] [Abstract][Full Text] [Related]
85. A review of the association between interleukin-10 and human B-cell malignancies.
Khatri VP; Caligiuri MA
Cancer Immunol Immunother; 1998 Jul; 46(5):239-44. PubMed ID: 9690451
[No Abstract] [Full Text] [Related]
86. Discovery of a Series of 5,11-Dihydro-6
Ferguson FM; Ni J; Zhang T; Tesar B; Sim T; Kim ND; Deng X; Brown JR; Zhao JJ; Gray NS
ACS Med Chem Lett; 2016 Oct; 7(10):908-912. PubMed ID: 27774127
[TBL] [Abstract][Full Text] [Related]
87. A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer.
Mekala N; Buddepu SR; Dehury SK; Moturu KMVR; Indukuri SKV; Vasireddi UR; Parimi AR
RSC Adv; 2018 Apr; 8(28):15863-15869. PubMed ID: 35539498
[TBL] [Abstract][Full Text] [Related]
88. Correction: Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents.
Vishakantegowda AG; Hwang D; Chakrasali P; Jung E; Lee JY; Shin JS; Jung YS
RSC Med Chem; 2024 Jun; 15(6):2196-2197. PubMed ID: 38911159
[TBL] [Abstract][Full Text] [Related]
89. Identifying selective PI3KC2α inhibitors.
Crunkhorn S
Nat Rev Drug Discov; 2022 Nov; 21(11):798. PubMed ID: 36192643
[No Abstract] [Full Text] [Related]
90. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
91. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
Meadows SA; Vega F; Kashishian A; Johnson D; Diehl V; Miller LL; Younes A; Lannutti BJ
Blood; 2012 Feb; 119(8):1897-900. PubMed ID: 22210877
[TBL] [Abstract][Full Text] [Related]
92. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
93. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR; Sharman JP; Coutre SE; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn I; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Stilgenbauer S; Cramer P; Aiello M; Johnson DM; Miller LL; Li D; Jahn TM; Dansey RD; Hallek M; O'Brien SM
N Engl J Med; 2014 Mar; 370(11):997-1007. PubMed ID: 24450857
[TBL] [Abstract][Full Text] [Related]
94. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
95. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
96. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Flinn IW; Kahl BS; Leonard JP; Furman RR; Brown JR; Byrd JC; Wagner-Johnston ND; Coutre SE; Benson DM; Peterman S; Cho Y; Webb HK; Johnson DM; Yu AS; Ulrich RG; Godfrey WR; Miller LL; Spurgeon SE
Blood; 2014 May; 123(22):3406-13. PubMed ID: 24615776
[TBL] [Abstract][Full Text] [Related]
97. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
[TBL] [Abstract][Full Text] [Related]
98. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Kahl BS; Spurgeon SE; Furman RR; Flinn IW; Coutre SE; Brown JR; Benson DM; Byrd JC; Peterman S; Cho Y; Yu A; Godfrey WR; Wagner-Johnston ND
Blood; 2014 May; 123(22):3398-405. PubMed ID: 24615778
[TBL] [Abstract][Full Text] [Related]
99. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ; Furman M; Winer ES
Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
[TBL] [Abstract][Full Text] [Related]
100. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
